Track topics on Twitter Track topics that are important to you
SAN DIEGO, Sept. 7, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held, leading regenerative medicine company, today announced upcoming scientific presentations. ViaCyte is developing nov...
SAN DIEGO, Oct. 4, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced upcoming company presentations at the Cell and Gene Meeting on the Mesa and ...
SAN DIEGO, Sept. 28, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced that the California Institute for Regenerative Medicine (CIRM) approved a ...
SAN DIEGO, Sept. 21, 2017 /PRNewswire/ -- Today, ViaCyte announced that its PEC-Direct™ product candidate has been selected as one of three finalists for CONNECT's Most Innovative New Product A...
The first participants have been treated with a novel islet replacement therapy in a new clinical trial, according to a press release from ViaCyte. The islet replacement cell therapy (PEC-Direct, Vita...
SummaryViaCyte Inc ViaCyte, formerly Novocell, Inc. is a regenerative medicine company that focuses on the development of cell replacement therapies for the treatment of diabetes. The company's pipeli...
The purpose of this study is to determine the effectiveness of the ViaCyte media for freezing and thawing human eggs for future use in assisted reproductive technology.
We have published hundreds of ViaCyte, Inc. news stories on BioPortfolio along with dozens of ViaCyte, Inc. Clinical Trials and PubMed Articles about ViaCyte, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ViaCyte, Inc. Companies in our database. You can also find out about relevant ViaCyte, Inc. Drugs and Medications on this site too.